L3VLUP
ProSign in

CHRS in the 13F filings

Coherus Oncology Inc · CUSIP 19249H103

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Quarter end
30 Sep 2021
the date the book describes
Filed
19 Oct 2021
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2021 and Q3 2021; 1 listed it in both
Shares listed
1,605
combined, among listed positions
Reported value
$26k
combined, at the quarter end

Managers listing CHRS in Q3 2021

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2021, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Baillie Gifford & Co1,605$26kunder 0.1%Trimmed-20219 Oct 2021 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2021 to Q3 2021, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q3 2022 to 1 in Q2 2024

Tracked managers listing it, at least.

02468201920202021202220232024
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
CHRS by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20151$3.7mn.a.n.a.
Q3 20152$5.5mn.a.n.a.
Q4 20151$2.9mn.a.n.a.
Q3 20161$27mn.a.n.a.
Q4 20161$17mn.a.n.a.
Q2 20181$12mn.a.n.a.
Q3 20182$142mn.a.n.a.
Q1 20193$17mn.a.n.a.
Q2 20193$155mn.a.n.a.
Q3 20191$133mn.a.n.a.
Q4 20195$13mn.a.n.a.
Q1 20207$65mn.a.n.a.
Q2 20202$75mn.a.n.a.
Q3 20203$86mn.a.n.a.
Q4 20204$85mn.a.n.a.
Q1 20213$3.3mn.a.n.a.
Q2 20213$3.1mn.a.n.a.
Q3 20211$26kn.a.n.a.
Q4 20214$95mn.a.n.a.
Q1 20223$78mn.a.n.a.
Q2 20221$10kn.a.n.a.
Q3 20222$59mn.a.n.a.
Q4 20221$13kn.a.n.a.
Q1 20232$778kn.a.n.a.
Q2 20231$2.1mn.a.n.a.
Q3 20233$2.2mn.a.n.a.
Q4 20232$3.6m11
Q1 20242$3.0m20
Q2 20241$558k01

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

CHRS and GILD →CHRS and AMGN →CHRS and ARGX →Choose a stock to compare with CHRS →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own CHRS, latest filings →Back to the 13F Explorer →